Migraine treatment with rizatriptan and non-triptan usual care medications: A pharmacy-based study

被引:8
|
作者
Cady, R
Martin, V
Adelman, J
Diamond, M
Sajjan, S
Hu, XH
机构
[1] Merck & Co Inc, Outcomes Res & Management, W Point, PA 19486 USA
[2] Primary Care Network Inc, Headache Care Ctr, Springfield, MO USA
[3] Univ Cincinnati, Div Gen Internal Med, Cincinnati, OH USA
[4] Headache Wellness Ctr, Greensboro, NC USA
[5] Diamond Headache Clin Ltd, Chicago, IL USA
来源
HEADACHE | 2004年 / 44卷 / 09期
关键词
migraine; migraine acute treatment; rizatriptan; non-triptan usual care medications;
D O I
10.1111/j.1526-4610.2004.04172.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To compare the effectiveness of rizatriptan to other non-triptan medications in the relief of migraine headache in usual care settings. Background.-Although rizatriptan has been shown to provide effective relief of migraine symptoms in clinical trials, limited data exist directly comparing its effectiveness with non-triptan medications. Methods.-Migraineurs aged 18 to 55 who had been prescribed a new antimigraine drug (rizatriptan 10 mg or a selected class of non-triptan oral medications) were recruited to participate in the study through a national retail pharmacy chain. Participants completed a baseline questionnaire at the enrollment and reported their treatment experiences by filling out the treatment diary after using the newly prescribed medication. The treatment outcomes of patients receiving rizatriptan were compared with those receiving non-triptan medications. Logistic regression analysis was applied to test statistical significance with adjustment for potential confounding factors. Results.-Of the 728 patients who entered the study, 693 (95.2%) completed the treatment diary. Patients treated with rizatriptan (192) and non-triptans (501) reported the following outcomes, respectively-onset of headache relief within 30 minutes post-dose: 25% versus 18%; self-defined significant headache relief within 2 hours post-dose: 71% versus 54%; pain free or mild pain at 2 hours post-dose: 58% versus 47%; completely symptom-free within 2 hours of post-dose: 32% versus 20%; return to usual activities within 2 hours post-dose: 39% versus 35%; and satisfied with treatment: 67% versus 55% (P < .05 in all comparisons with exception of returning to usual activities). Conclusion.-Rizatriptan was significantly more effective than non-triptans in the relief of migraine headaches for patients obtaining prescribed migraine medications from a retail pharmacy. Additional studies at other usual care settings may be needed to confirm the findings.
引用
收藏
页码:900 / 907
页数:8
相关论文
共 50 条
  • [31] Evaluating the sustained effectiveness of a novel pharmacy-based intervention to reduce older adult misuse of over-the-counter medications: A case for non-significance
    Gilson, Aaron M.
    Stone, Jamie A.
    Berbakov, Maria E.
    Hoffins, Emily L.
    Gollhardt, Joel
    Walker, Kenneth
    Chui, Michelle A.
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2025, 21 (04): : 253 - 261
  • [32] Community pharmacy-based opiate substitution treatment and related health services: a study of 508 patients and 111 pharmacies
    Laird A.
    Hunter C.
    Sardar C.M.
    Fitzgerald N.M.
    Lowrie R.
    Journal of Public Health, 2016, 24 (3) : 193 - 207
  • [33] Community pharmacy-based point-of-care testing: A case study of pharmacist-physician collaborative working relationships
    Bacci, Jennifer L.
    Klepser, Donald
    Tilley, Heather
    Smith, Jaclyn K.
    Klepser, Michael E.
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2018, 14 (01): : 112 - 115
  • [34] LABOR-MARKET AFFILIATION AMONG DANISH MIGRAINE PATIENTS DISCONTINUING TRIPTAN TREATMENT-A REGISTER-BASED STUDY
    Ashina, M.
    Hansen, T. F.
    Hansen, J. M.
    Hauberg, D.
    US, Lonberg
    Steiner, T. J.
    VALUE IN HEALTH, 2023, 26 (12) : S247 - S247
  • [35] Stakeholders' perceptions and practices regarding hypertension, pharmacy-based care, and e-monitoring in urban Nigeria: a mixed methods study
    Cremers, A. L.
    Alege, A.
    Nelissen, H. E.
    Okwor, T.
    Gerrets, R. P. M.
    Van 't Hoog, A. H.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2017, 22 : 366 - 366
  • [36] Patients' and healthcare providers' perceptions and practices regarding hypertension, pharmacy-based care, and mHealth in Lagos, Nigeria: a mixed methods study
    Cremers, Anne L.
    Alege, Abiola
    Nelissen, Heleen E.
    Okwor, Tochi J.
    Osibogun, Akin
    Gerrets, Rene
    Van't Hoog, Anja H.
    JOURNAL OF HYPERTENSION, 2019, 37 (02) : 389 - 397
  • [37] Use of a primary care and pharmacy-based model for the delivery of injectable opioid agonist treatment for severe opioid use disorder: a case report
    Wilson, Tyler
    Brar, Rupi
    Sutherland, Christy
    Nolan, Seonaid
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (05) : E115 - E117
  • [38] Use of Non-vitamin K antagonist Oral Anticoagulants in a real-world setting: a community pharmacy-based study
    Capiau, A.
    Mehuys, E.
    Van Tongelen, I.
    De Backer, T.
    Christiaens, T.
    De Sutter, A.
    Steurbaut, S.
    Moudallel, S.
    Rydant, S.
    Boussery, K.
    EUROPEAN HEART JOURNAL, 2019, 40 : 160 - 160
  • [39] Determinants of Non-Adherence to Antidiabetic Drug Treatments: A Study Using a Psychosocial Theoretical Framework and Pharmacy-Based Adherence Measures
    Guenette, Line
    Zongo, Arsene
    Guillaumie, Laurence
    Lauzier, Sophie
    Blais, Lucie
    Gregoire, Jean-Pierre
    Moisan, Jocelyne
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 239 - 240
  • [40] "Pharmacy-based care model for the treatment of opioid use disorder: pilot findings and novel care adaptations during COVID-19" (MM11)
    Green, Traci C.
    McKenzie, Michelle
    Serafinski, Rachel
    Clark, Seth
    Langdon, Kirsten
    Rich, Josiah
    Bratberg, Jeffrey
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2020, 15 (SUPPL 2):